Next Article in Journal
Autophagic Markers in Chordomas: Immunohistochemical Analysis and Comparison with the Immune Microenvironment of Chordoma Tissues
Previous Article in Journal
Immuno-PET Molecular Imaging of RANKL in Cancer
Review

Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma

1
Faculty of Medicine, McGill University, Montreal, QC H3G 2M1, Canada
2
Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada
3
Departments of Medicine and Oncology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Aldo M. Roccaro
Cancers 2021, 13(9), 2167; https://doi.org/10.3390/cancers13092167
Received: 13 April 2021 / Revised: 27 April 2021 / Accepted: 27 April 2021 / Published: 30 April 2021
(This article belongs to the Section Molecular Cancer Biology)
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). Despite the genetic heterogeneity of the disease, most patients are initially treated with a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), but relapse occurs in ~50% of patients. One of the hallmarks of DLBCL is the occurrence of genetic events that inhibit apoptosis, which contributes to disease development and resistance to therapy. These events can affect the intrinsic or extrinsic apoptotic pathways, or their modulators. Understanding the factors that contribute to inhibition of apoptosis in DLBCL is crucial in order to be able to develop targeted therapies and improve outcomes, particularly in relapsed and refractory DLBCL (rrDLBCL). This review provides a description of the genetic events inhibiting apoptosis in DLBCL, their contribution to lymphomagenesis and chemoresistance, and their implication for the future of DLBCL therapy.
Diffuse large B cell lymphoma (DLBCL) is curable with chemoimmunotherapy in ~65% of patients. One of the hallmarks of the pathogenesis and resistance to therapy in DLBCL is inhibition of apoptosis, which allows malignant cells to survive and acquire further alterations. Inhibition of apoptosis can be the result of genetic events inhibiting the intrinsic or extrinsic apoptotic pathways, as well as their modulators, such as the inhibitor of apoptosis proteins, P53, and components of the NF-kB pathway. Mechanisms of dysregulation include upregulation of anti-apoptotic proteins and downregulation of pro-apoptotic proteins via point mutations, amplifications, deletions, translocations, and influences of other proteins. Understanding the factors contributing to resistance to apoptosis in DLBCL is crucial in order to be able to develop targeted therapies that could improve outcomes by restoring apoptosis in malignant cells. This review describes the genetic events inhibiting apoptosis in DLBCL, provides a perspective of their interactions in lymphomagenesis, and discusses their implication for the future of DLBCL therapy. View Full-Text
Keywords: diffuse large B cell lymphoma; non-Hodgkin lymphoma; apoptosis; genetics; BCL2; NF-kB; TP53; mutations; translocations; amplifications diffuse large B cell lymphoma; non-Hodgkin lymphoma; apoptosis; genetics; BCL2; NF-kB; TP53; mutations; translocations; amplifications
Show Figures

Figure 1

MDPI and ACS Style

Leveille, E.; Johnson, N.A. Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma. Cancers 2021, 13, 2167. https://doi.org/10.3390/cancers13092167

AMA Style

Leveille E, Johnson NA. Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma. Cancers. 2021; 13(9):2167. https://doi.org/10.3390/cancers13092167

Chicago/Turabian Style

Leveille, Etienne, and Nathalie A. Johnson 2021. "Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma" Cancers 13, no. 9: 2167. https://doi.org/10.3390/cancers13092167

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop